A semisynthetic analgesic used in the study of narcotic receptors. It has abuse potential. PubChem
Fitur visualisasi ini dikembangkan menggunakan pendekatan Graph Theory untuk memetakan hubungan polifarmasi dan molekuler. Entitas (Obat, Target, Gen) direpresentasikan sebagai Simpul (Nodes), sedangkan hubungan biologisnya sebagai Sisi (Edges).
drugbank-id dan name pada skema XML DrugBank.targets/target yang memuat polipeptida sasaran.gene-name dan varian snp-effects.Tata letak grafik menggunakan algoritma Force-Directed Graph (Barnes-Hut). Model fisika ini menerapkan gaya tolak-menolak antar simpul (Gravitasi: -3000) agar tidak tumpang tindih, serta gaya pegas (Spring: 0.04) pada garis penghubung untuk fleksibilitas interaksi.
| Buprenorphine | Dihydromorphine may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine. |
| Doxylamine | Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Dihydromorphine. |
| Dronabinol | Dronabinol may increase the central nervous system depressant (CNS depressant) activities of Dihydromorphine. |
| Droperidol | Droperidol may increase the central nervous system depressant (CNS depressant) activities of Dihydromorphine. |
| Hydrocodone | Dihydromorphine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone. |
| Hydroxyzine | Hydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Dihydromorphine. |
| Magnesium sulfate | The therapeutic efficacy of Dihydromorphine can be increased when used in combination with Magnesium sulfate. |
| Methotrimeprazine | Dihydromorphine may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine. |
| Metyrosine | Dihydromorphine may increase the sedative activities of Metyrosine. |
| Minocycline | Minocycline may increase the central nervous system depressant (CNS depressant) activities of Dihydromorphine. |
| Nabilone | Nabilone may increase the central nervous system depressant (CNS depressant) activities of Dihydromorphine. |
| Orphenadrine | Dihydromorphine may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine. |
| Paraldehyde | Dihydromorphine may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde. |
| Perampanel | Perampanel may increase the central nervous system depressant (CNS depressant) activities of Dihydromorphine. |
| Pramipexole | Dihydromorphine may increase the sedative activities of Pramipexole. |
| Ropinirole | Dihydromorphine may increase the sedative activities of Ropinirole. |
| Rotigotine | Dihydromorphine may increase the sedative activities of Rotigotine. |
| Rufinamide | The risk or severity of adverse effects can be increased when Rufinamide is combined with Dihydromorphine. |
| Sodium oxybate | Dihydromorphine may increase the central nervous system depressant (CNS depressant) activities of Sodium oxybate. |
| Suvorexant | Dihydromorphine may increase the central nervous system depressant (CNS depressant) activities of Suvorexant. |
| Tapentadol | Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Dihydromorphine. |
| Thalidomide | Dihydromorphine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide. |
| Zolpidem | Dihydromorphine may increase the central nervous system depressant (CNS depressant) activities of Zolpidem. |
| Alvimopan | The risk or severity of adverse effects can be increased when Dihydromorphine is combined with Alvimopan. |
| Desmopressin | The risk or severity of hyponatremia can be increased when Dihydromorphine is combined with Desmopressin. |
| Morphine | The risk or severity of adverse effects can be increased when Morphine is combined with Dihydromorphine. |
| Codeine | The risk or severity of adverse effects can be increased when Codeine is combined with Dihydromorphine. |
| Hydromorphone | The risk or severity of adverse effects can be increased when Hydromorphone is combined with Dihydromorphine. |
| Meperidine | The risk or severity of adverse effects can be increased when Meperidine is combined with Dihydromorphine. |
| Oxycodone | The risk or severity of adverse effects can be increased when Oxycodone is combined with Dihydromorphine. |
| Dextropropoxyphene | The risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Dihydromorphine. |
| Naltrexone | The therapeutic efficacy of Dihydromorphine can be decreased when used in combination with Naltrexone. |
| Sufentanil | The risk or severity of adverse effects can be increased when Sufentanil is combined with Dihydromorphine. |
| Alfentanil | The risk or severity of adverse effects can be increased when Alfentanil is combined with Dihydromorphine. |
| Fentanyl | The risk or severity of adverse effects can be increased when Fentanyl is combined with Dihydromorphine. |
| Levorphanol | The risk or severity of adverse effects can be increased when Levorphanol is combined with Dihydromorphine. |
| Remifentanil | The risk or severity of adverse effects can be increased when Remifentanil is combined with Dihydromorphine. |
| Diphenoxylate | The risk or severity of adverse effects can be increased when Diphenoxylate is combined with Dihydromorphine. |
| Oxymorphone | The risk or severity of adverse effects can be increased when Oxymorphone is combined with Dihydromorphine. |
| Dezocine | The risk or severity of adverse effects can be increased when Dezocine is combined with Dihydromorphine. |
| Methadyl acetate | The risk or severity of adverse effects can be increased when Methadyl acetate is combined with Dihydromorphine. |
| Dihydroetorphine | The risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Dihydromorphine. |
| Diamorphine | The risk or severity of adverse effects can be increased when Diamorphine is combined with Dihydromorphine. |
| Bezitramide | The risk or severity of adverse effects can be increased when Bezitramide is combined with Dihydromorphine. |
| Ethylmorphine | The risk or severity of adverse effects can be increased when Ethylmorphine is combined with Dihydromorphine. |
| Etorphine | The risk or severity of adverse effects can be increased when Etorphine is combined with Dihydromorphine. |
| Dextromoramide | The risk or severity of adverse effects can be increased when Dextromoramide is combined with Dihydromorphine. |
| Desomorphine | The risk or severity of adverse effects can be increased when Desomorphine is combined with Dihydromorphine. |
| Carfentanil | The risk or severity of adverse effects can be increased when Carfentanil is combined with Dihydromorphine. |
| Dihydrocodeine | The risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Dihydromorphine. |
| Alphacetylmethadol | The risk or severity of adverse effects can be increased when Alphacetylmethadol is combined with Dihydromorphine. |
| Ketobemidone | The risk or severity of adverse effects can be increased when Dihydromorphine is combined with Ketobemidone. |
| DPDPE | The risk or severity of adverse effects can be increased when Dihydromorphine is combined with DPDPE. |
| Lofentanil | The risk or severity of adverse effects can be increased when Dihydromorphine is combined with Lofentanil. |
| Opium | The risk or severity of adverse effects can be increased when Dihydromorphine is combined with Opium. |
| Normethadone | The risk or severity of adverse effects can be increased when Dihydromorphine is combined with Normethadone. |
| Piritramide | The risk or severity of adverse effects can be increased when Dihydromorphine is combined with Piritramide. |
| Alphaprodine | The risk or severity of adverse effects can be increased when Dihydromorphine is combined with Alphaprodine. |
| Nicomorphine | The risk or severity of adverse effects can be increased when Dihydromorphine is combined with Nicomorphine. |
| Meptazinol | The therapeutic efficacy of Dihydromorphine can be decreased when used in combination with Meptazinol. |
| Phenoperidine | The risk or severity of adverse effects can be increased when Dihydromorphine is combined with Phenoperidine. |
| Phenazocine | The risk or severity of adverse effects can be increased when Dihydromorphine is combined with Phenazocine. |
| Tilidine | The risk or severity of adverse effects can be increased when Dihydromorphine is combined with Tilidine. |
| Carfentanil, C-11 | The risk or severity of adverse effects can be increased when Dihydromorphine is combined with Carfentanil, C-11. |
| Naloxegol | The risk or severity of adverse effects can be increased when Dihydromorphine is combined with Naloxegol. |
| Benzhydrocodone | The risk or severity of adverse effects can be increased when Dihydromorphine is combined with Benzhydrocodone. |
| Pegvisomant | The therapeutic efficacy of Pegvisomant can be decreased when used in combination with Dihydromorphine. |
| Succinylcholine | The risk or severity of bradycardia can be increased when Succinylcholine is combined with Dihydromorphine. |
| Methadone | The risk or severity of adverse effects can be increased when Methadone is combined with Dihydromorphine. |
| Linezolid | The risk or severity of serotonin syndrome can be increased when Linezolid is combined with Dihydromorphine. |
| Mirtazapine | Dihydromorphine may increase the serotonergic activities of Mirtazapine. |
| Fluvoxamine | The risk or severity of serotonin syndrome can be increased when Dihydromorphine is combined with Fluvoxamine. |
| Citalopram | The risk or severity of serotonin syndrome can be increased when Dihydromorphine is combined with Citalopram. |
| Duloxetine | The risk or severity of serotonin syndrome can be increased when Dihydromorphine is combined with Duloxetine. |
| Paroxetine | The risk or severity of serotonin syndrome can be increased when Dihydromorphine is combined with Paroxetine. |
| Sertraline | The risk or severity of serotonin syndrome can be increased when Dihydromorphine is combined with Sertraline. |
| Sibutramine | The risk or severity of serotonin syndrome can be increased when Dihydromorphine is combined with Sibutramine. |
| Nefazodone | The risk or severity of serotonin syndrome can be increased when Dihydromorphine is combined with Nefazodone. |
| Zimelidine | The risk or severity of serotonin syndrome can be increased when Dihydromorphine is combined with Zimelidine. |
| Dapoxetine | The risk or severity of serotonin syndrome can be increased when Dihydromorphine is combined with Dapoxetine. |
| Milnacipran | The risk or severity of serotonin syndrome can be increased when Dihydromorphine is combined with Milnacipran. |
| Desvenlafaxine | The risk or severity of serotonin syndrome can be increased when Desvenlafaxine is combined with Dihydromorphine. |
| Seproxetine | The risk or severity of serotonin syndrome can be increased when Dihydromorphine is combined with Seproxetine. |
| Levomilnacipran | The risk or severity of serotonin syndrome can be increased when Dihydromorphine is combined with Levomilnacipran. |
| Indalpine | The risk or severity of serotonin syndrome can be increased when Dihydromorphine is combined with Indalpine. |
| Ritanserin | The risk or severity of serotonin syndrome can be increased when Dihydromorphine is combined with Ritanserin. |
| Alaproclate | The risk or severity of serotonin syndrome can be increased when Dihydromorphine is combined with Alaproclate. |
| Ethanol | Dihydromorphine may increase the central nervous system depressant (CNS depressant) activities of Ethanol. |
| Azelastine | Dihydromorphine may increase the central nervous system depressant (CNS depressant) activities of Azelastine. |
| Brimonidine | Brimonidine may increase the central nervous system depressant (CNS depressant) activities of Dihydromorphine. |
| Phentermine | Phentermine may increase the analgesic activities of Dihydromorphine. |
| Pseudoephedrine | Pseudoephedrine may increase the analgesic activities of Dihydromorphine. |
| Benzphetamine | Benzphetamine may increase the analgesic activities of Dihydromorphine. |
| Diethylpropion | Diethylpropion may increase the analgesic activities of Dihydromorphine. |
| Lisdexamfetamine | The risk or severity of serotonin syndrome can be increased when Dihydromorphine is combined with Lisdexamfetamine. |
| Mephentermine | Mephentermine may increase the analgesic activities of Dihydromorphine. |
| MMDA | MMDA may increase the analgesic activities of Dihydromorphine. |
| Midomafetamine | Midomafetamine may increase the analgesic activities of Dihydromorphine. |
| 2,5-Dimethoxy-4-ethylamphetamine | 2,5-Dimethoxy-4-ethylamphetamine may increase the analgesic activities of Dihydromorphine. |
| 4-Bromo-2,5-dimethoxyamphetamine | 4-Bromo-2,5-dimethoxyamphetamine may increase the analgesic activities of Dihydromorphine. |